A downloadable version of the Winter 2009 issue of BioPreservation Today can be found here: http://www.biolifesolutions.com/docs/bpt/bptwinter09.pdf.
BioLife Solutions will be presenting and exhibiting at the Phacilitate Cell & Gene Therapy Forum 2009, January 26-28 in Washington, DC (http://www.phacilitate.co.uk/pages/cgtherapy/index.html).
About BioLife Solutions, Inc.:
BioLife Solutions develops and markets patented hypothermic storage/transport and cryopreservation media products for cells, tissues, and organs. The Company's proprietary HypoThermosol(R) and CryoStor(TM) platform of biopreservation media products are marketed to academic research institutions, hospitals, and commercial companies involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's GMP products are serum-free and protein-free, fully defined, and pre-formulated to reduce preservation-induced, delayed-onset cell damage and death. Comprehensive small animal intravenous safety studies have been completed on HypoThermosol and CryoStor, and both products are supported by US FDA Master Files. BioLife's enabling technology provides research and clinical organizations significantly enhanced in post-preservation cell and tissue viability and function.
For more information please visit http://www.biolifesolutions.com.
This news release contains forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
forward-looking statements include any statements that relate to the intent,
belief, plans or expectations of the Company or its management, or that are
not a st
|SOURCE BioLife Solutions, Inc.|
Copyright©2009 PR Newswire.
All rights reserved